Curis (CRIS) to Release Earnings on Tuesday

Curis (NASDAQ:CRIS) is anticipated to announce its Q1 2025 earnings results before the market opens on Tuesday, May 6th. Analysts expect Curis to post earnings of ($1.39) per share and revenue of $2.37 million for the quarter.

Curis (NASDAQ:CRIS) last issued its earnings results on Monday, March 31st. The biotechnology company reported ($1.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.36) by $0.11. Curis had a negative return on equity of 923.37% and a negative net margin of 443.35%. The business had revenue of $2.70 million during the quarter, compared to analyst estimates of $2.04 million. On average, analysts expect Curis to post $-7 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Curis Stock Performance

CRIS stock opened at $2.41 on Friday. The company has a market capitalization of $20.46 million, a PE ratio of -0.31 and a beta of 3.51. Curis has a one year low of $1.02 and a one year high of $16.93. The company’s 50 day moving average price is $2.09 and its two-hundred day moving average price is $3.18.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on CRIS. HC Wainwright decreased their target price on shares of Curis from $20.00 to $16.00 and set a “buy” rating on the stock in a research report on Monday, March 31st. StockNews.com began coverage on Curis in a report on Wednesday. They issued a “hold” rating on the stock.

Curis Company Profile

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.